Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116930 · ClinicalTrials.gov registry record · Phase 2
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
A Phase 2 study of Post-Dural Puncture Headache, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05116930 is a Phase 2 study of Post-Dural Puncture Headache that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05116930, a Phase 2 study of Post-Dural Puncture Headache, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.
Conditions Studied
Interventions
- DRUG Neostigmine
- DRUG Glycopyrrolate
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05116930
The ClinicalTrials.gov registry entry for NCT05116930 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-Dural Puncture Headache appearing as the primary indexed condition, and to 2 interventions - of which Neostigmine is the first listed.
NCT05116930 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05116930 about?
NCT05116930 is a clinical study titled "Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture". The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.
What is the current status of trial NCT05116930?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-11-19. Estimated completion is 2027-12.
What conditions does trial NCT05116930 study?
This clinical trial studies the following conditions: Post-Dural Puncture Headache.
What interventions are being tested in trial NCT05116930?
The interventions under investigation include: Neostigmine (DRUG), Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT05116930?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05116930 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.